Research / SWKHL / Fundamental state Inspectable configuration
State dimensions Filing 0001552781-21-000666 Bank
Net-income growth 100th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.net_income
1494.75% · CORE · VALID
Interest-expense growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.financial.interest_expense
-42.33% · CORE · NOT_ENOUGH_HISTORY
Cash and equivalents 15th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.cash
$6.6M · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 23 states Self-history eligible
Sep 30, 2020 2/3 normalized Level 3 Dec 31, 2020 2/3 normalized Level 3 Jun 30, 2021 2/3 normalized Level 3 Sep 30, 2021 2/3 normalized Level 3 Dec 31, 2021 3/3 normalized Level 3 Mar 31, 2022 3/3 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 3/3 normalized Level 3 Dec 31, 2022 3/3 normalized Level 3 Mar 31, 2023 3/3 normalized Level 3 Jun 30, 2023 3/3 normalized Level 3 Sep 30, 2023 3/3 normalized Level 3 Dec 31, 2023 3/3 normalized Level 3 Mar 31, 2024 3/3 normalized Level 3 Jun 30, 2024 3/3 normalized Level 3 Dec 31, 2024 2/3 normalized Level 3 Mar 31, 2025 2/3 normalized Level 3 Jun 30, 2025 2/3 normalized Level 3 Sep 30, 2025 2/3 normalized Level 3 Dec 31, 2025 2/3 normalized Level 4 Period transition
What moved in the state? Funding Cost Growth Decreased
Previous 43.56%
Current -42.33%
Delta -85.90% Liquidity Increased
Previous $1.6M
Current $6.6M
Delta $5.0M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.